With seven commercially available programs, Hughes said the company is building a “diverse and growing source of recurring receipts.” He pointed to early-stage commercial launches for Day One Biopharmaceuticals’ OJEMDA and Zevra Therapeutics’ MIPLYFFA, and noted that both companies submitted marketing authorizations in the European Union in 2025. Hughes also cited Ipsen’s Feb. 26, 2026 announcement of a positive CHMP opinion recommending conditional marketing authorization for OJEMDA in the EU. He added tha ...